-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Following Recent Decline, Sino Biopharmaceutical Limited's (HKG:1177) Top Shareholder CEO Eric S. Y. Tse Sees Holdings Value Drop by 5.8%
Following Recent Decline, Sino Biopharmaceutical Limited's (HKG:1177) Top Shareholder CEO Eric S. Y. Tse Sees Holdings Value Drop by 5.8%
If you want to know who really controls Sino Biopharmaceutical Limited (HKG:1177), then you'll have to look at the makeup of its share registry. We can see that individual insiders own the lion's share in the company with 36% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And last week, insiders endured the biggest losses as the stock fell by 5.8%.
Let's take a closer look to see what the different types of shareholders can tell us about Sino Biopharmaceutical.
Check out our latest analysis for Sino Biopharmaceutical
SEHK:1177 Ownership Breakdown August 25th 2022What Does The Institutional Ownership Tell Us About Sino Biopharmaceutical?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
We can see that Sino Biopharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Sino Biopharmaceutical, (below). Of course, keep in mind that there are other factors to consider, too.
SEHK:1177 Earnings and Revenue Growth August 25th 2022We note that hedge funds don't have a meaningful investment in Sino Biopharmaceutical. The company's CEO Eric S. Y. Tse is the largest shareholder with 22% of shares outstanding. France Investment (China 1) Group Limited is the second largest shareholder owning 12% of common stock, and Ping Tse holds about 8.7% of the company stock. Interestingly, the third-largest shareholder, Ping Tse is also a Vice Chairman, again, indicating strong insider ownership amongst the company's top shareholders.
To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
Insider Ownership Of Sino Biopharmaceutical
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems insiders own a significant proportion of Sino Biopharmaceutical Limited. Insiders own HK$27b worth of shares in the HK$75b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
General Public Ownership
With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Sino Biopharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
It seems that Private Companies own 12%, of the Sino Biopharmaceutical stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Sino Biopharmaceutical better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Sino Biopharmaceutical .
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道谁真正控制了中国生物制药股份有限公司(HKG:1177),那么你就得看看它的股份登记处的构成。我们可以看到,个人内部人士拥有公司的最大份额,拥有36%的股份。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
上周,内部人士遭受了最大的损失,该股下跌5.8%。
让我们仔细看看不同类型的股东能告诉我们关于中国生物制药的什么。
看看我们对中国生物制药的最新分析
联交所:1177拥有权分类2022年8月25日关于中国生物制药,机构所有制告诉了我们什么?
许多机构以一个接近当地市场的指数来衡量它们的表现。因此,他们通常更关注那些被纳入主要指数的公司。
我们可以看到,中国生物制药确实有机构投资者,他们持有公司很大一部分股票。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这一事实,因为机构有时会做出糟糕的投资,就像每个人一样。如果两个大型机构投资者试图同时抛售一只股票,股价大幅下跌的情况并不少见。因此,值得查看中国生物制药过去的收入轨迹(见下图)。当然,请记住,还有其他因素需要考虑。
联交所:1177盈利及收入增长2022年8月25日我们注意到,对冲基金并没有对中国生物制药进行有意义的投资。该公司首席执行长谢霆锋(Eric S.Y.Tse)是最大股东,持有22%的流通股。法国投资(中国一)集团有限公司是第二大股东,持有12%的普通股,平泽持有公司约8.7%的股份。有趣的是,第三大股东谢平也是副董事长,这再次表明公司的大股东拥有强大的内部人所有权。
为了让我们的研究更有趣,我们发现,前5名股东控制着公司一半以上的股份,这意味着这一群体对公司的决策具有相当大的影响力。
虽然研究一家公司的机构持股可以增加你的研究价值,但研究分析师的建议以更深入地了解一只股票的预期表现也是一个很好的做法。有相当数量的分析师追踪该股,因此了解他们对未来的总体看法可能是有用的。
中国生物制药的内部人所有权
公司内部人的定义可能是主观的,而且在不同的司法管辖区之间确实有所不同。我们的数据反映了个别内部人士,至少捕捉到了董事会成员。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
内部人士似乎持有中国生物制药股份有限公司相当大的比例。内部人士持有这家市值750亿港元的公司价值270亿港元的股票。这是很有意义的。很高兴看到这样的投资水平。你可以在这里查看这些内部人士最近是否一直在买入。
一般公有制
拥有33%股权的普通公众,主要由个人投资者组成,对中国生物制药有一定程度的影响力。虽然这群人不一定能发号施令,但它肯定能对公司的运营方式产生真正的影响。
私营公司所有权
看起来,民营企业持有中国生物制药12%的股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但要更好地理解中国生物制药,我们还需要考虑许多其他因素。为此,您应该意识到1个警告标志我们已经看到了中国生物制药。
但最终这就是未来,而不是过去,这将决定这家企业的所有者将做得多好。因此,我们认为,看看这份免费报告是明智的,它显示了分析师是否预测到了更光明的未来。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧